{
      "Rank": 442,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m^2) + Chlorpheniramine (1 mg for 2~6 years old; 2 mg for 6~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.",
            "Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m^2) + Chlorpheniramine (1 mg for 2~6 years old; 2 mg for 6~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001."
      ],
      "ArmGroupInterventionName": [
            "Drug: EN001",
            "Drug: EN001"
      ],
      "ArmGroupLabel": [
            "Dose group A (Low dose)",
            "Dose group B (High dose)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT05338099"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Duchenne Muscular Dystrophy(DMD)"
      ],
      "BriefTitle": [
            "Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "August 19, 2028"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Duchenne Muscular Dystrophy"
      ],
      "ConditionAncestorId": [
            "D000020966",
            "D000009135",
            "D000009140",
            "D000009468",
            "D000009422",
            "D000030342",
            "D000040181"
      ],
      "ConditionAncestorTerm": [
            "Muscular Disorders, Atrophic",
            "Muscular Diseases",
            "Musculoskeletal Diseases",
            "Neuromuscular Diseases",
            "Nervous System Diseases",
            "Genetic Diseases, Inborn",
            "Genetic Diseases, X-Linked"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "BC10",
            "BC16",
            "All",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "Nervous System Diseases",
            "Diseases and Abnormalities at or Before Birth",
            "All Conditions",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Muscular Dystrophy",
            "Duchenne Muscular Dystrophy",
            "Muscular Dystrophy",
            "Duchenne Muscular Dystrophy",
            "Duchenne Muscular Dystrophy"
      ],
      "ConditionBrowseLeafId": [
            "M11245",
            "M21338",
            "M3741",
            "M11244",
            "M21850",
            "M11249",
            "M11563",
            "M22839",
            "M24030",
            "T3963",
            "T698",
            "T1945"
      ],
      "ConditionBrowseLeafName": [
            "Muscular Dystrophies",
            "Muscular Dystrophy, Duchenne",
            "Atrophy",
            "Muscular Diseases",
            "Muscular Disorders, Atrophic",
            "Musculoskeletal Diseases",
            "Neuromuscular Diseases",
            "Genetic Diseases, Inborn",
            "Genetic Diseases, X-Linked",
            "Muscular Dystrophy",
            "Becker Muscular Dystrophy",
            "Duchenne Muscular Dystrophy"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000009136",
            "D000020388"
      ],
      "ConditionMeshTerm": [
            "Muscular Dystrophies",
            "Muscular Dystrophy, Duchenne"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Sequential Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "It is the first in human (FIH), 3+3 design clinical trial to evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) in the treatment of Duchenne Muscular Dystrophy (DMD)."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nThose aged 2 to 18 years old\nMale\nThose who are diagnosed with DMD due to a mutation in the dystrophin gene identified by a genetic test\n\nPhenotypic evidence of DMD\n\nClinical signs or symptoms (proximal weakness, waddling gait, Gowers maneuver)\nElevated serum creatine kinase level\nThose who have been using systemic corticosteroids at a stable dose for 24 weeks prior to screening and are expected to maintain the constant dose throughout the study period\nThose who agree to use effective contraceptive measures until the short-term follow-up period of the clinical trial. In addition, their partner must also use a medically acceptable method of contraception (ie, oral contraceptives for women) for the same period.\nThose who are willing to agree with the ICF and whose parent or representative is willing to provide written consent for the subject's participation in the clinical trial\n\nExclusion Criteria:\n\nThose who have clinical signs or symptoms of cardiomyopathy, defined as LVEF <50% on echocardiography at screening\nIf ventilatory support is required during the day or if invasive mechanical ventilation via tracheostomy is used (Non-invasive ventilation such as positive pressure ventilation is allowed at night)\nIf hepatitis B core antibody and hepatitis C antibody are positive\nIf there is a history of major surgery within 12 weeks or it is expected during the study period\nThose who have been exposed to gene therapy or genome editing within 24 weeks from the screening\nThose who have experience with stem cell therapy\nThose who have been administered Translarna granules (Ataluren) within 24 weeks from the screening\nThose who are receiving treatment (other than corticosteroids) that may affect muscle strength or function within 12 weeks prior to screening\n\nIf laboratory test values are abnormal at the time of screening\n\nHemoglobin <10 g/dL\nSerum albumin <2.5 g/dL\nPlatelet count <50,000/ml\nAbnormal GGT or total bilirubin (>laboratory's upper limit of normal)\nAbnormal renal function (Serum creatinine >1.5 Times laboratory's upper limit of normal)\"\nThose with significant neuromuscular or genetic diseases other than DMD\nThose with significant heart, lung, liver, kidney, hematological, immunological, behavioral disease, or other clinically significant diseases including malignant tumors\nThose who have a previous or current medical condition that may adversely affect the safety of the subject, make it difficult to complete treatment, or affect the evaluation of clinical trial results at the discretion of the investigator\nThose who do not have the will or ability to comply with clinical trial procedures at the discretion of the investigator"
      ],
      "EnrollmentCount": [
            "12"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "Male"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Dose group A (Low dose)",
            "Dose group B (High dose)"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Antipy",
            "Analg",
            "All",
            "AnEm",
            "CNSDep",
            "PsychDr",
            "Derm",
            "Gast",
            "Infl",
            "AAll",
            "AntiConv"
      ],
      "InterventionBrowseBranchName": [
            "Antipyretics",
            "Analgesics",
            "All Drugs and Chemicals",
            "Antiemetics",
            "Central Nervous System Depressants",
            "Psychotropic Drugs",
            "Dermatologic Agents",
            "Gastrointestinal Agents",
            "Anti-Inflammatory Agents",
            "Anti-Allergic Agents",
            "Anticonvulsants"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M2341",
            "M18740",
            "M9064",
            "M155022",
            "M228602",
            "M263157",
            "M5137",
            "M10292"
      ],
      "InterventionBrowseLeafName": [
            "Acetaminophen",
            "Ondansetron",
            "Hydrocortisone",
            "Hydrocortisone 17-butyrate 21-propionate",
            "Hydrocortisone acetate",
            "Hydrocortisone hemisuccinate",
            "Chlorpheniramine",
            "Lorazepam"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.\n\nDose group A (Low dose): 5.0x10^5 cells/kg",
            "EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.\n\nDose group B (High dose): 2.5x10^6 cells/kg"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "EN001",
            "EN001"
      ],
      "InterventionOtherName": [
            "EN001 (allogeneic umbilical cord-derived mesenchymal stem cells)",
            "EN001 (allogeneic umbilical cord-derived mesenchymal stem cells)"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 13, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 12, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "ENCell"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Seoul"
      ],
      "LocationContactEMail": [
            "encell@encellinc.com"
      ],
      "LocationContactName": [
            "ENCell Co., Ltd."
      ],
      "LocationContactPhone": [
            "+82-2-6205-8040"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact"
      ],
      "LocationCountry": [
            "Korea, Republic of"
      ],
      "LocationFacility": [
            "Samsung Medical Center"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [],
      "MaximumAge": [
            "18 Years"
      ],
      "MinimumAge": [
            "2 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "ENCell"
      ],
      "OrgStudyId": [
            "ENCell_2020_01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "January 31, 2023"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Number of participants with treatment-related adverse events as assessed by CTCAE v5.0",
            "Among the adverse events occurring for 2 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE 5.0",
            "Among the adverse events occurring for 2 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE 5.0 Maximum tolerated dose defines the evaluated maximum dose level in which greater than two participants of six participants experience Dose-limiting toxicity (DLT) under the dose level. The dose level where two participants of six participants experience DLT will be the maximum tolerated dose.",
            "Vital Signs include blood pressure (mmHg), pulse (times/minute), respiratory rate (times/minute), and body temperature (\u2103) and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001.\n\nThe number of participants with at least one potentially clinically significant abnormal vital sign finding were reported as treatment emergent adverse events (TEAEs).",
            "Physical Examinations include general appearance, head, ears/eyes/nose/throat, cardiovascular, respiratory, abdomen, skin, lymph nodes, extremities, musculoskeletal and neurologic and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001.\n\nNumber of participants with potentially clinically significant abnormalities in physical examinations were reported as TEAEs.",
            "Laboratory Parameters include hematology, chemistry laboratory tests, urinalysis, coagulation test and plasma viral load test and will be assessed by CTCAE 5.0 to evaluate safety and tolerability of EN001.\n\nNumber of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs.",
            "Categorical summarization ECG criteria were as follows:\n\nQT interval, QTcB, QTcF and QTcP: increase from baseline >30 millisecond [ms] or 60 ms; absolute value > 450 ms, >480 ms, and > 500 ms;\nheart rate (HR): change from baseline \u226520 beats per minute [bpm] and absolute value\u226450 bpm or \u2265120 bpm;\nPR interval: absolute value \u2265220 ms and increase from baseline\u226520 ms;\nQRS: \u2265120 ms."
      ],
      "PrimaryOutcomeMeasure": [
            "Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product",
            "Determination of Dose-limiting toxicity (DLT) levels of EN001",
            "Determination of Maximum tolerated dose (MTD) levels of EN001",
            "Number of participants with Vital Signs abnormalities",
            "Number of participants with clinically significant abnormalities of Physical Examinations",
            "Number of participants with abnormalities of Laboratory Parameters",
            "Number of participants with abnormalities of 12-lead Electrocardiography (ECG)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Week 12 after treatment",
            "Up to Week 2 after dosing on Day 0",
            "Up to Week 2 after dosing on Day 0",
            "Week 12 after screening",
            "From screening up to Week 12",
            "From screening up to Week 12",
            "From screening to baseline on Day 0 (Predose to end of infusion and 90 min after completion of infusion)"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Occurrence of any adverse reactions, development of new blood clots, tumors, immune responses (like autoimmune reactions) and death, and/or serious adverse events related investigational product will be summarized by actual treatment groups respectively.",
            "Abnormalities of Vital Signs, Physical Findings, and Laboratory parameters (as described above) will be collected and analyzed, and then assessed by CTCAE 5.0 to evaluate the long-term safety of EN001.",
            "Creatinine kinase (CK) level will be collected and analyzed to evaluate the exploratory efficacy of EN001.\n\n- CK level(%) = (CK level after dosing - CK level in baseline)/(CK level in baseline)*100",
            "Function tests measured by North Star Ambulatory Assessment (NSAA), Six Minute Walk Test (6MWT), Myometry. and Lung capacity (and only K-Cross Motor Function Measure (KGMFM) will be performed under 5 years old) will be collected and analyzed to evaluate the exploratory efficacy of EN001.\n\n- Function tests = value in visit - value in baseline"
      ],
      "SecondaryOutcomeMeasure": [
            "Incidence of adverse events (AEs)",
            "Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters",
            "Rate of change at the time of visit compared to baseline (percent [%]) in CK level",
            "Change from baseline in Function tests"
      ],
      "SecondaryOutcomeTimeFrame": [
            "From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)",
            "From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)",
            "From screening up to the end of support (up to approximately 5 years per subject at each visit)",
            "Screening and baseline on Day -1 (up to approximately 5 years per subject after Week 12)"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 18, 2022"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "May 2022"
      ],
      "StdAge": [
            "Child",
            "Adult"
      ],
      "StudyFirstPostDate": [
            "April 20, 2022"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "January 6, 2022"
      ],
      "StudyFirstSubmitQCDate": [
            "April 18, 2022"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}